1. Home
  2. AKTX vs USEG Comparison

AKTX vs USEG Comparison

Compare AKTX & USEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • USEG
  • Stock Information
  • Founded
  • AKTX N/A
  • USEG 1966
  • Country
  • AKTX United States
  • USEG United States
  • Employees
  • AKTX N/A
  • USEG N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • USEG Oil & Gas Production
  • Sector
  • AKTX Health Care
  • USEG Energy
  • Exchange
  • AKTX Nasdaq
  • USEG Nasdaq
  • Market Cap
  • AKTX 41.8M
  • USEG 42.2M
  • IPO Year
  • AKTX N/A
  • USEG N/A
  • Fundamental
  • Price
  • AKTX $1.18
  • USEG $1.53
  • Analyst Decision
  • AKTX
  • USEG Strong Buy
  • Analyst Count
  • AKTX 0
  • USEG 1
  • Target Price
  • AKTX N/A
  • USEG $3.50
  • AVG Volume (30 Days)
  • AKTX 27.7K
  • USEG 9.2M
  • Earning Date
  • AKTX 08-18-2025
  • USEG 08-06-2025
  • Dividend Yield
  • AKTX N/A
  • USEG N/A
  • EPS Growth
  • AKTX N/A
  • USEG N/A
  • EPS
  • AKTX N/A
  • USEG N/A
  • Revenue
  • AKTX N/A
  • USEG $16,340,000.00
  • Revenue This Year
  • AKTX N/A
  • USEG $23.82
  • Revenue Next Year
  • AKTX N/A
  • USEG N/A
  • P/E Ratio
  • AKTX N/A
  • USEG N/A
  • Revenue Growth
  • AKTX N/A
  • USEG N/A
  • 52 Week Low
  • AKTX $0.85
  • USEG $0.81
  • 52 Week High
  • AKTX $4.40
  • USEG $6.40
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 44.68
  • USEG 52.63
  • Support Level
  • AKTX $1.09
  • USEG $1.44
  • Resistance Level
  • AKTX $1.22
  • USEG $1.69
  • Average True Range (ATR)
  • AKTX 0.08
  • USEG 0.29
  • MACD
  • AKTX -0.00
  • USEG -0.02
  • Stochastic Oscillator
  • AKTX 40.00
  • USEG 23.83

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About USEG U.S. Energy Corp. (DE)

US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.

Share on Social Networks: